Corporate
News release
TopTOKYO, JAPAN - September 20, 2019 - Terumo Corporation (TSE: 4543) today announced that it will construct an additional production facility for pre-filled syringes at the headquarter plant of Terumo Yamaguchi D&D Corporation, a Terumo subsidiary. The capital investment for the project will total approximately JPY 2 billion. The investments announced today and on July 9, 2018 will increase the production capacity at Terumo Yamaguchi D&D by approximately 2.5 times compared to the current capability.
Terumo Yamaguchi D&D Corporation operates a plant that produces Drug and Device (D&D) products, which combines medical devices with pharmaceutical drugs in a single product. The plant manufactures D&D products such as Hulio™ (adalimumab biosimilar)*1, which is currently available in Europe, and Teribone™ 28.2 µg subcutaneous autoinjector*2, which will be marketed in Japan.
The Alliance Division offers advanced devices to pharmaceutical companies, utilizing the experience and expertise Terumo has built up through years of prefilled device manufacturing. Every drug not only differs in its effects, but also has varying characteristics and usage situations. Terumo develops tailor made drug administration devices, such as syringes and needles materials suitable to each drug. Terumo also provides contract manufacturing, which leverages the company's advanced manufacturing technology of drug delivery device and combination product. The annual revenue ended March 2019 of the Alliance Division was JPY 20.4 billion, which was 30% growth year-on-year and contributed greatly to the overall Terumo group growth. The division is expected as the growth driver force for the General Hospital Company.
- *1:
The product of FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
- *2:
The product of Asahi Kasei Pharma Corporation
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.